Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 3

Sponsor Class

UNKNOWN 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 13138Triple Negative Breast Neoplasms 1150Neoplasms 750Ovarian Neoplasms 680Neoplasm Metastasis 590Lung Neoplasms 582Colorectal Neoplasms 581Prostatic Neoplasms 560Carcinoma, Non-Small-Cell Lung 536Pancreatic Neoplasms 380Melanoma 366Stomach Neoplasms 350Colonic Neoplasms 330Motor Activity 285Breast Neoplasms, Male 285Carcinoma, Intraductal, Noninfiltrating 277Uterine Cervical Neoplasms 267Head and Neck Neoplasms 266Endometrial Neoplasms 256Carcinoma, Renal Cell 216Sarcoma 204Urinary Bladder Neoplasms 192Squamous Cell Carcinoma of Head and Neck 192Lymphedema 190Esophageal Neoplasms 189Breast Carcinoma In Situ 189Brain Neoplasms 183Fatigue 166Carcinoma, Ovarian Epithelial 151Small Cell Lung Carcinoma 148

Interventions

palbociclib 1Vinorelbine 1Fulvestrant 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hormone Receptor Positive Advanced Breast Cancer × Breast × Clear all
NCT05000736 2022-04-29

CAPACITY

ChineseAMS

Unknown
600 enrolled
Breast

Hormone Receptor Positive Advanced Breast Cancer

NCT05343117 2022-04-26

Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

ChineseAMS

Unknown
400 enrolled
Breast

Hormone Receptor Positive Advanced Breast Cancer

NCT03939871 2020-06-23

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
30 enrolled
Breast

Hormone Receptor Positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡